Press coverage about PAREXEL International (NASDAQ:PRXL) has been trending somewhat positive on Sunday, according to Accern. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. PAREXEL International earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 49.2788591872216 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
NASDAQ:PRXL opened at $88.08 on Friday. PAREXEL International has a 1 year low of $51.16 and a 1 year high of $88.10. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.45 and a quick ratio of 1.45.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact PAREXEL International (PRXL) Share Price” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/parexel-international-prxl-receives-daily-coverage-optimism-rating-of-0-13.html.
PAREXEL International Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International and related companies with MarketBeat.com's FREE daily email newsletter.